SWM
AUPH icon

Sugarloaf Wealth Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Sugarloaf Wealth Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed -$1K – 837
2022
Q2 		$1K Buy
+100
New +$1.12K ﹤0.01% 723

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sugarloaf Wealth Management's AUPH Position: Q3 2022 in Review

Sugarloaf Wealth Management sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2022, closing a stake of 100 shares — an estimated $1K sold.

Sugarloaf Wealth Management first reported a position in AUPH in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 189 funds tracked by Wall St. Rank hold AUPH as of Q3 2022.

  • Sugarloaf Wealth Management reported no remaining Aurinia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Sugarloaf Wealth Management sold 100 Aurinia Pharmaceuticals shares in Q3 2022, an estimated $1K.
  • Sugarloaf Wealth Management first reported a position in Aurinia Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Sugarloaf Wealth Management's Aurinia Pharmaceuticals position peaked at $1K in Q2 2022.
  • 189 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2022.

Based on Sugarloaf Wealth Management's 13F filing for Q3 2022, filed 11 Oct 2022.